SusanLeePerlmanMD

Neurology • Los Angeles, CA

Movement Disorder, Neurodegenerative, Neurodevelopmental Disabilities

Professor, Neurology, UCLA School of Medicine

Join to view full profile

Dr. Perlman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Perlman's full profile

Already have an account?

Office
300 Medical Plz
# B200
Los Angeles, CA 90095
Phone+1 310-794-1195

Fax+1 310-794-7491

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Neurology, 1976 - 1979
UCLA David Geffen School of Medicine/UCLA Medical CenterInternship, Internal Medicine, 1975 - 1976
Stony Brook University Health Sciences Center School of MedicineClass of 1975

Certifications & Licensure

CA State Medical License 1976 - 2026
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

Super Doctor SuperDoctors.com

Clinical Trials

Neurobiological Predictors of Huntington's Disease (PREDICT-HD) Start of enrollment: 2002 Aug 01
Active, not recruiting
Study to Assess the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Start of enrollment: 2007 Dec 01
Completed
Phase 3
Study to Assess the Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients Start of enrollment: 2008 Jul 01
Completed
Phase 3
Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias Start of enrollment: 2010 Apr 01
Recruiting
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort Start of enrollment: 2012 Jul 01
Recruiting
FA Clinical Outcome Measures Start of enrollment: 2001 Jan 01
Recruiting
Neurology Measures in FA Children Start of enrollment: 2017 Nov 20
Completed
Instrumented Data Exchange for Ataxia Study Start of enrollment: 2019 Jun 01
Active, not recruiting
Join now to see all

Publications & Presentations

PubMed

1 citations
Clinical, Radiological and Pathological Features of a Large American Cohort of Spinocerebellar Ataxia (SCA27B).
Widad Abou Chaar, Anirudh N Eranki, Hannah A Stevens, Sonya L Watson, Darice Y Wong
Annals of Neurology. 2024-12-01
2 citations
Content Validity of the Modified Functional Scale for the Assessment and Rating of Ataxia (f-SARA) Instrument in Spinocerebellar Ataxia.
Michele Potashman, Katja Rudell, Ivanna Pavisic, Naomi Suminski, Rinchen Doma
Cerebellum. 2024-10-01
Assessment of the reliability, responsiveness, and meaningfulness of the scale for the assessment and rating of ataxia (SARA) for lysosomal storage disorders.
Julien Park, Tatiana Bremova-Ertl, Marion Brands, Tomas Foltan, Matthias Gautschi
Journal of Neurology. 2024-10-01

Press Mentions

Skyclarys (Omaveloxolone) Becomes the First FDA-Approved Treatment for Friedreich’s AtaxiaMarch 10th, 2023
FDA Approves SkyclarysJanuary 3rd, 2023
Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio ProgressDecember 8th, 2022
Join now to see all